mRNA-LNP vaccines: rational design, delivery optimization, and clinical translation
Source abstract
Abstract
Messenger RNA (mRNA) vaccines face core challenges including low-delivery efficiency and immunogenicity, limiting their wide-ranging applications in infectious disease prevention and cancer therapy. Lipid nanoparticles (LNPs), the most clinically validated non-viral delivery platform, address these challenges by encapsulating and protecting mRNA, promoting cellular uptake, and mediating endosomal escape. mRNA-LNP vaccines leverage a "rapid design + flexible production" advantage, decisively demonstrated by the success of COVID-19 vaccines such as BNT162b2. This review systematically analyzes mRNA-LNP vaccine development, focusing on core optimization strategies: (1) mRNA sequence engineering (nucleoside modification and UTR/poly(A) tail optimization) to enhance stability and translation efficiency; (2) LNP formulation (component ratio optimization, SPOT strategies, etc.) to modulate immune responses and enable organ targeting; and (3) LNP surface functionalization (with small molecules, peptides, and antibodies) for precise specific cell or organ targeting. Although multiple candidate vaccines for infectious disease prevention and cancer treatment have entered clinical trials, their clinical translation is still limited by insufficient targeting accuracy, potential immunogenicity and toxicity, and the challenge of universal delivery systems. Future breakthroughs require the integration of multidisciplinary innovations, focusing on the development of degradable lipids and novel targeting ligands to improve delivery precision, the application of more biocompatible polymers (such as pSar and POx) to replace PEG to enhance safety, and the use of artificial intelligence (AI) to accelerate LNP formulation design and performance prediction. This review summarizes the key optimization strategies and clinical progress and explores future directions to overcome the existing bottlenecks and promote mRNA-LNP technology as the cornerstone of next-generation precision medicine.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · RNA and protein synthesis mechanisms · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemical and Biological Engineering Zhejiang University Hangzhou, Zhejiang 310058, China
Institute of Zhejiang University, Quzhou 99 Zheda Road, Quzhou, Zhejiang 324000, China
References (100+)
Show source-provided references
1. Sahin · Nature · 2017 · 547 · 22210.1038/nature23003 ↗
2. Sayour · Nat. Rev. Clin. Oncol. · 2024 · 21 · 48910.1038/s41571-024-00902-1 ↗
3. Zhang · Signal Transduction Targeted Ther. · 2023 · 8 · 36510.1038/s41392-023-01579-1 ↗
4. Zaidi · Nat. Rev. Cancer · 2025 · 25 · 51710.1038/s41568-025-00820-z ↗
5. Chen · Nat. Rev. Methods Primers · 2023 · 3 · 6310.1038/s43586-023-00246-7 ↗
6. Karikó · Immunity · 2005 · 23 · 16510.1016/j.immuni.2005.06.008 ↗
7. Hajj · Nat. Rev. Mater. · 2017 · 2 · 1705610.1038/natrevmats.2017.56 ↗
8. Meng · Adv. Ther. · 2021 · 4 · 200009910.1002/adtp.202000099 ↗
9. Zong · Adv. Mater. · 2023 · 35 · 230326110.1002/adma.202303261 ↗
10. Sui · J. Mater. Chem. B · 2025 · 13 · 1008510.1039/D5TB01556A ↗
11. Polack Fernando · N. Engl. J. Med. · 2020 · 383 · 260310.1056/NEJMoa2034577 ↗
12. Anderson Evan · N. Engl. J. Med. · 2020 · 383 · 242710.1056/NEJMoa2028436 ↗
13. Baden Lindsey · N. Engl. J. Med. · 2021 · 384 · 40310.1056/NEJMoa2035389 ↗
14. Dowdy · Nat. Biotechnol. · 2017 · 35 · 22210.1038/nbt.3802 ↗
15. Weng · Biotechnol. Adv. · 2020 · 40 · 10753410.1016/j.biotechadv.2020.107534 ↗
16. Juliano · Nucleic Acid Ther. · 2014 · 24 · 10110.1089/nat.2013.0463 ↗
17. Verbeke · Immunity · 2022 · 55 · 199310.1016/j.immuni.2022.10.014 ↗
18. Hornung · Nat. Med. · 2005 · 11 · 26310.1038/nm1191 ↗
19. Chow · Annu. Rev. Immunol. · 2018 · 36 · 66710.1146/annurev-immunol-042617-053309 ↗
20. Udepurkar · ACS Nano · 2025 · 19 · 2120610.1021/acsnano.4c18274 ↗
21. Witten · Proc. Natl. Acad. Sci. U. S. A. · 2024 · 121 · e230779812010.1073/pnas.2307798120 ↗
22. Chen · Coord. Chem. Rev. · 2025 · 543 · 21694510.1016/j.ccr.2025.216945 ↗
23. Sun · Pharm. Res. · 2023 · 40 · 2710.1007/s11095-022-03460-2 ↗
24. Sabnis · Mol. Ther. · 2018 · 26 · 150910.1016/j.ymthe.2018.03.010 ↗
25. Alameh · Immunity · 2021 · 54 · 287710.1016/j.immuni.2021.11.001 ↗
26. Semple · Biochim. Biophys. Acta, Biomembr. · 2001 · 1510 · 15210.1016/S0005-2736(00)00343-6 ↗
27. Patel · Trends Pharmacol. Sci. · 2021 · 42 · 44810.1016/j.tips.2021.03.002 ↗
28. Maniyamgama · J. Mater. Chem. B · 2025 · 13 · 1217210.1039/D5TB00470E ↗
29. Schlich · Bioeng. Transl. Med. · 2021 · 6 · e1021310.1002/btm2.10213 ↗
30. Semple · Nat. Biotechnol. · 2010 · 28 · 17210.1038/nbt.1602 ↗
31. Tang · Adv. NanoBiomed. Res. · 2023 · 3 · 230000610.1002/anbr.202300006 ↗
32. Miao · Nat. Biotechnol. · 2019 · 37 · 117410.1038/s41587-019-0247-3 ↗
33. Dilliard · Proc. Natl. Acad. Sci. U. S. A. · 2021 · 118 · e210925611810.1073/pnas.2109256118 ↗
34. Semple · Nat. Biotechnol. · 2010 · 28 · 17210.1038/nbt.1602 ↗
35. Kim · Adv. Drug Delivery Rev. · 2021 · 170 · 8310.1016/j.addr.2020.12.014 ↗
36. Jain · Blood · 2023 · 142 · 682810.1182/blood-2023-181406 ↗
37. Cornebise · Adv. Funct. Mater. · 2022 · 32 · 210672710.1002/adfm.202106727 ↗
38. Han · Nat. Chem. · 2024 · 16 · 168710.1038/s41557-024-01557-2 ↗
39. Chen · Angew. Chem., Int. Ed. · 2025 · 64 · e20250695410.1002/anie.202506954 ↗
40. Han · Nat. Commun. · 2021 · 12 · 723310.1038/s41467-021-27493-0 ↗
41. Dong · Proc. Natl. Acad. Sci. U. S. A. · 2014 · 111 · 395510.1073/pnas.1322937111 ↗
42. Heyes · J. Controlled Release · 2005 · 107 · 27610.1016/j.jconrel.2005.06.014 ↗
43. Fenton · Adv. Mater. · 2016 · 28 · 293910.1002/adma.201505822 ↗
44. Maier · Mol. Ther. · 2013 · 21 · 157010.1038/mt.2013.124 ↗
45. Khan · Sci. Adv. · 2018 · 4 · eaar840910.1126/sciadv.aar8409 ↗
46. Hajj · Small · 2019 · 15 · e180509710.1002/smll.201805097 ↗
47. Hashiba · Small Sci. · 2023 · 3 · 220007110.1002/smsc.202200071 ↗
48. Zhi · Adv. Colloid Interface Sci. · 2018 · 253 · 11710.1016/j.cis.2017.12.006 ↗
49. Zou · Int. J. Pharm. · 2022 · 617 · 12159610.1016/j.ijpharm.2022.121596 ↗
50. De Lombaerde · Adv. Funct. Mater. · 2024 · 34 · 231062310.1002/adfm.202310623 ↗
51. Younis · Drug Delivery Transl. Res. · 2025 · 15 · 362610.1007/s13346-025-01824-w ↗
52. Chen · Proc. Natl. Acad. Sci. U. S. A. · 2022 · 119 · e220784111910.1073/pnas.2207841119 ↗
53. Zhang · Proc. Natl. Acad. Sci. U. S. A. · 2021 · 118 · e200519111810.1073/pnas.2005191118 ↗
54. Cheng · Viruses · 2023 · 15 · 66810.3390/v15030668 ↗
55. Kauffman · Nano Lett. · 2015 · 15 · 730010.1021/acs.nanolett.5b02497 ↗
56. Zhang · Biomater. Sci. · 2021 · 9 · 144910.1039/D0BM01609H ↗
57. Álvarez-Benedicto · Biomater. Sci. · 2022 · 10 · 54910.1039/D1BM01454D ↗
58. Luozhong · Nano Lett. · 2022 · 22 · 830410.1021/acs.nanolett.2c03234 ↗
59. Yang · J. Controlled Release · 2025 · 384 · 11389210.1016/j.jconrel.2025.113892 ↗
60. Hatit · Nat. Chem. · 2023 · 15 · 50810.1038/s41557-023-01138-9 ↗
61. Patel · Nat. Commun. · 2020 · 11 · 98310.1038/s41467-020-14527-2 ↗
62. Liu · ACS Appl. Mater. Interfaces · 2025 · 17 · 441610.1021/acsami.4c14203 ↗
63. Aldosari · Pharmaceutics · 2021 · 13 · 20610.3390/pharmaceutics13020206 ↗
64. Lokugamage · Nat. Biomed. Eng. · 2021 · 5 · 105910.1038/s41551-021-00786-x ↗
65. Hald Albertsen · Adv. Drug Delivery Rev. · 2022 · 188 · 11441610.1016/j.addr.2022.114416 ↗
66. Suzuki · Int. J. Pharm. · 2020 · 588 · 11979210.1016/j.ijpharm.2020.119792 ↗
67. Song · Biochim. Biophys. Acta, Biomembr. · 2002 · 1558 · 110.1016/S0005-2736(01)00399-6 ↗
68. Mui · Mol. Ther. – Nucleic Acids · 2013 · 2 · e13910.1038/mtna.2013.66 ↗
69. Gao · ACS Nano · 2025 · 19 · 596610.1021/acsnano.4c09399 ↗
70. Fu · Nano Today · 2024 · 55 · 10216310.1016/j.nantod.2024.102163 ↗
71. Deuker · Nanoscale Horiz. · 2023 · 8 · 137710.1039/D3NH00198A ↗
72. Ju · ACS Nano · 2022 · 16 · 1176910.1021/acsnano.2c04543 ↗
73. Semple · J. Pharmacol. Exp. Ther. · 2005 · 312 · 102010.1124/jpet.104.078113 ↗
74. Holick · Small · 2025 · 21 · 241135410.1002/smll.202411354 ↗
75. Sanchez · Adv. Healthcare Mater. · 2024 · 13 · e230403310.1002/adhm.202304033 ↗
76. Kang · Bioact. Mater. · 2024 · 37 · 86
77. Luozhong · Nat. Mater. · 2025 · 24 · 185210.1038/s41563-025-02240-8 ↗
78. Duan · Small · 2013 · 9 · 152110.1002/smll.201201390 ↗
79. Kim · Sci. Adv. · 2021 · 7 · eabf439810.1126/sciadv.abf4398 ↗
80. O’Brien Laramy · Mol. Pharm. · 2023 · 20 · 428510.1021/acs.molpharmaceut.3c00390 ↗
81. Bi · Adv. Healthcare Mater. · 2024 · 13 · 240125210.1002/adhm.202401252 ↗
82. Geng · J. Controlled Release · 2023 · 364 · 63210.1016/j.jconrel.2023.11.017 ↗
83. Tang · J. Nanobiotechnol. · 2025 · 23 · 22310.1186/s12951-025-03318-w ↗
84. Metkar · Nat. Rev. Drug Discovery · 2024 · 23 · 6710.1038/s41573-023-00827-x ↗
85. Warminski · J. Am. Chem. Soc. · 2024 · 146 · 814910.1021/jacs.3c12629 ↗
86. Jia · Acc. Chem. Res. · 2021 · 54 · 427210.1021/acs.accounts.1c00541 ↗
87. Kim · Adv. Drug Delivery Rev. · 2021 · 170 · 8310.1016/j.addr.2020.12.014 ↗
88. Wadhwa · Pharmaceutics · 2020 · 12 · 10210.3390/pharmaceutics12020102 ↗
89. Ma · Sci. Rep. · 2024 · 14 · 1984510.1038/s41598-024-70792-x ↗
90. Adibzadeh · Avicenna J. Med. Biotechnol. · 2019 · 11 · 112
91. Passmore · Nat. Rev. Mol. Cell Bio. · 2022 · 23 · 9310.1038/s41580-021-00417-y ↗
92. Chen · Nat. Biotechnol. · 2025 · 43 · 19410.1038/s41587-024-02174-7 ↗
93. Pardi · Nat. Rev. Drug Discovery · 2024 · 23 · 83810.1038/s41573-024-01042-y ↗
94. Xu · Mol. Pharm. · 2025 · 22 · 8110.1021/acs.molpharmaceut.4c00863 ↗
95. Suzuki · J. Controlled Release · 2025 · 382 · 11368710.1016/j.jconrel.2025.113687 ↗
96. Cheng · Nat. Nanotechnol. · 2020 · 15 · 31310.1038/s41565-020-0669-6 ↗
97. Vadovics · Nat. Nanotechnol. · 2025 · 20 · 131210.1038/s41565-025-01958-5 ↗
98. Wang · Nat. Protoc. · 2023 · 18 · 26510.1038/s41596-022-00755-x ↗
99. Kim · Nat. Biotechnol. · 202510.1038/s41587-025-02675-z ↗
100. Luo · ACS Nano · 2024 · 18 · 3070110.1021/acsnano.4c09902 ↗